Cellerant Therapeutics, a San Carlos, Calif. developer of stem cell therapeutics for things like sickle cell disease treatment, has raised $4.4 million in a second round financing. It was reported by VentureWire (sub required), which cited a Securities and Exchange Commission filing.

Cellerant previously raised $25 million towards its Series B funding, having last added $9 million to the round in September 2005. Before that, the company also raised a $10 million funding in May 2003. Cellerant’s investors include Camelot Ventures, Eminent Venture Capital Group, Amgen Founder George Rathmann, Novel Bioventures, CX Venture Group, MPM Capital, Allen & Co. and BD Ventures.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.